Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.58 |
| ▸ | CDK1 | P06493 | 7/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.56 |
| ▸ | CDK9 | P50750 | 5/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.54 |
| ▸ | CDK7 | P50613 | 4/20 | 0.54 |
| ▸ | CCNH | P51946 | 3/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110978 | 0.87 | CYP2C9 (0.57) | CDK2CDK1CCNB1CDK9CCNT1 | |
| SCHEMBL4098291 | 0.86 | CYP2C19 (0.51) | CDK2CDK1CCNB1CCNA2CCNB2 | |
| SCHEMBL13561275 | 0.84 | CDK1 (0.55) | CDK2CDK1CCNB1CDK9CCNT1 | |
| SCHEMBL4119336 | 0.83 | CYP2C9 (0.52) | CDK2CDK1CCNB1CDK9CCNT1 | |
| SCHEMBL13561268 | 0.82 | CYP2C9 (0.55) | CDK2CDK1CCNB1CDK9CCNT1 | |
| SCHEMBL4106873 | 0.81 | CYP2C19 (0.47) | CDK2CDK1CCNB1CCNA2CCNB2 | |
| SCHEMBL4105100 | 0.80 | CYP2C9 (0.51) | CDK2CDK1CCNB1CDK9CCNT1 | |
| SCHEMBL4113585 | 0.80 | CYP2C9 (0.52) | CDK2CCNA2CCNA1CYP2C9CYP2C19 | |
| SCHEMBL13561277 | 0.79 | CYP2C9 (0.50) | CDK2CDK1CCNB1CDK9CCNT1 | |
| SCHEMBL4105261 | 0.79 | CYP2C9 (0.47) | CDK2CDK1CCNB1CCNA2CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | CDK2 212/4885CDK1 572/4885CCNB1 1393/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | CDK2 212/4885CDK1 572/4885CCNB1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.